

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A polymeric drug delivery system, comprising:
 - (a) a biodegradable water insoluble block copolymer that is a solid or wax at 37°C, comprising greater than 50% hydrophobic blocks and less than 50% hydrophilic blocks ;
 - (b) a biodegradable water soluble polymer that is a liquid at 25°C, wherein the insoluble block copolymer and the soluble polymer are at a weight ratio within the range of 30:70 to 70:30; and
 - (c) a hydrophobic drug, wherein said polymeric drug delivery system is a liquid or paste and injectable at 25°C.
- 2-4. Canceled.
5. (Currently Amended) The polymeric drug delivery system of claim ~~3~~1 wherein said water insoluble polymer is a triblock copolymer having the formula ABA, wherein each A is a hydrophobic block, and wherein B is a hydrophilic block.
- 6-62. Canceled.
63. (New) The polymeric drug delivery system of claim 1, wherein a hydrophobic block comprises one or more polymers selected from the group consisting of a polyester, polyanhydride, polybutyric acid, polyacrylic acid and polymethacrylate.

64. (New) The polymeric drug delivery system of claim 63, wherein the one or more polymers is a polyester selected from the group consisting of polylactic acid, polyglycolic acid, and polycaprolactone.

65. (New) The polymeric drug delivery system of claim 5, wherein each of said hydrophobic blocks comprises one or more polymers selected from the group consisting of a polyester, polyanhydride, polybutyric acid, polyacrylic acid and polymethacrylate.

66. (New) The polymeric drug delivery system of claim 65, wherein the one or more polymers is a polyester selected from the group consisting of polylactic acid, polyglycolic acid, and polycaprolactone.

67. (New) The polymeric drug delivery system of claim 5, wherein one or more hydrophobic blocks comprises a poly(α -hydroxy acid).

68. (New) The polymeric drug delivery system of claim 67, wherein said poly(α -hydroxy acid) is poly(glycolic acid) or poly(lactic acid).

69. (New) The polymeric drug delivery system of claim 1, wherein said hydrophilic block comprises a polyalkylene oxide.

70. (New) The polymeric drug delivery system of claim 69, wherein said polyalkylene oxide is polyethylene glycol.

71. (New) The polymeric drug delivery system of claim 5, wherein said hydrophilic block comprises a polyalkylene oxide.

72. (New) The polymeric drug delivery system of claim 71, wherein said polyalkylene oxide is polyethylene glycol.

73. (New) A polymeric drug delivery system, comprising:

(a) a biodegradable water insoluble block copolymer that is a solid or wax at 37°C, comprising greater than 50% hydrophobic blocks and less than 50% hydrophilic blocks;

(b) a biodegradable water soluble polymer that is a liquid at 25°C; and

(c) a hydrophobic drug, wherein said polymeric drug delivery system is a liquid or paste at 25°C, wherein said hydrophilic block comprises a polysaccharide.

74. (New) A polymeric drug delivery system, comprising:

(a) a biodegradable water insoluble block copolymer that is a solid or wax at 37°C, comprising greater than 50% hydrophobic blocks and less than 50% hydrophilic blocks;

(b) a biodegradable water soluble polymer that is a liquid at 25°C; and

(c) a hydrophobic drug, wherein said polymeric drug delivery system is a liquid or paste at 25°C,

wherein said water insoluble polymer is a triblock copolymer having the formula ABA, wherein each A is a hydrophobic block, and wherein B is a hydrophilic block;

wherein each of said hydrophobic blocks comprises one or more polymers selected from the group consisting of a polyester selected from the group consisting of polylactic acid, polyglycolic acid, and polycaprolactone; and

wherein the hydrophilic block comprises a polyalkylene oxide and the polyester and polyalkylene oxide components of said triblock copolymer are linked by caprolactone links.

75. (New) The polymeric drug delivery system of claim 74, wherein said triblock copolymer comprises [poly(DL-lactide-co-ε-caprolactone)]-[polyethylene glycol]-[poly(DL-lactide-co-ε-caprolactone)].

76. (New) The polymeric drug delivery system of claim 74, wherein said water soluble polymer is polyethylene glycol or methoxypolyethylene glycol.

77. (New) The polymeric drug delivery system of claim 76, wherein said water soluble polymer is methoxypolyethylene glycol having an average molecular weight of about 100-500.

78. (New) The polymeric drug delivery system of claim 77, wherein the triblock copolymer (TB) and said methoxypolyethylene glycol (MePEG) are present in said polymeric drug delivery system at a weight ratio of TB:MePEG within the range of 30:70 to 90:10.

79. (New) The polymeric drug delivery system of claim 74, wherein the weight of said hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system of 1% or more.

80. (New) The polymeric drug delivery system of claim 74, wherein the weight of said hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system within the range of 2-30%.

81. (New) The polymeric drug delivery system of claim 74, wherein said hydrophobic drug is selected from the group consisting of amphotericin, anthralin, beclomethasone, betamethasone, camptothecin, curcumin, dexamethasone, indomethacin, genistein, lidocaine, insulin, nystatin, paclitaxel, tetracycline, tretinoin, cromoglycate, levobunolol, and terbinafine.

82. (New) The polymeric drug delivery system of claim 81, wherein said hydrophobic drug is paclitaxel.

83. (New) A polymeric drug delivery system, comprising:

(a) a biodegradable water insoluble block copolymer that is a solid or wax at 37°C, comprising greater than 50% hydrophobic blocks and less than 50% hydrophilic blocks;

(b) a biodegradable water soluble polymer that is a liquid at 25°C; and

(c) a hydrophobic drug, wherein said polymeric drug delivery system is a liquid or paste at 25°C,

wherein said water insoluble polymer is a triblock copolymer having the formula ABA, wherein each A is a hydrophobic block, and wherein B is a hydrophilic block, wherein said hydrophilic block comprises a polyalkylene oxide, wherein the average molecular weight of the polyethylene glycol in the triblock copolymer is about 4600.

84. (New) The polymeric drug delivery system of claim 83, wherein the water soluble polymer is methoxypolyethylene glycol of an average molecular weight of about 350.

85. (New) The polymeric drug delivery system of claim 83, wherein the weight of the hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system of 1% or more.

86. (New) The polymeric drug delivery system of claim 83, wherein the weight of the hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system within the range of 2-30%.

87. (New) The polymeric drug delivery system of claim 83, wherein the hydrophobic drug is selected from the group consisting of amphotericin, anthralin, beclomethasone, betamethasone, camptothecin, curcumin, dexamethasone, indomethacin, genistein, lidocaine, insulin, nystatin, paclitaxel, tetracycline, tretinoin, cromoglycate, levobunolol, and terbinafine.

88. (New) The polymeric drug delivery system of claim 83, wherein the hydrophobic drug is selected from the group consisting of paclitaxel, camptothecin, amphoterecin, nystatin, tretinoin, genistein, and curcumin.

89. (New) The polymeric drug delivery system of claim 83, wherein the hydrophobic drug is paclitaxel.

90. (New) The polymeric drug delivery system of claim 1, wherein the weight of said hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system of 1% or more.

91. (New) The polymeric drug delivery system of claim 1, wherein the weight of said hydrophobic drug represents a percentage of the total weight of said polymeric drug delivery system within the range of 2-30%.

92. (New) The polymeric drug delivery system of claim 1, wherein said hydrophobic drug is selected from the group consisting of amphotericin, anthralin, beclomethasone, betamethasone, camptothecin, curcumin, dexamethasone, indomethacin, genistein, lidocaine, insulin, nystatin, paclitaxel, tetracycline, tretinoin, cromoglycate, levobunolol, and terbinafine.

93. (New) The polymeric drug delivery system of claim 1, wherein said hydrophobic drug is paclitaxel.